In this prototype design, no elements are placed over patient's eyes, nose, or mouth, which may improve comfort compared with conventional coils. In this image, identifiable portions of participant's face have been obscured for publication and privacy purposes. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)
December 4, 2020 — According to an article in ARRS' American Journal of Roentgenology (AJR), a prototype 16-channel head Adaptive Image Receive (AIR) radiofrequency coil from GE Healthcare outperformed a conventional 8-channel head coil for in vivo whole-brain imaging, though it did not perform as well as a conventional 32-channel head coil.
"This study shows the feasibility of the novel AIR coil technology for imaging the brain and provides insight for future coil design improvements," concluded first author Petrice M. Cogswell, M.D., Ph.D., of the Mayo Clinic in Rochester, Minnesota.
Lightweight and flexible with an open, ski-mask design, the emergent AIR coil technology exhibits electrical characteristics that overcome several of the limitations of traditional rigid coil designs.
Imaging a phantom and 15 healthy adult participants, Cogswell and colleagues used clinically available MRI sequences to compare their 16-channel head AIR coil with conventional 8- and 32-channel head coils. During consensus review, two board-certified neuroradiologists graded the AIR coil against the 8-channel coil and the 32-channel coil on a 5-point ordinal scale in multiple categories.
On average, the signal-to-noise ratio, structural sharpness, and overall image quality scores of the 16-channel AIR coil prototype were better than those of the 8-channel coil but not as good as those of the 32-channel coil.
Noise covariance matrices showed stable performance of the AIR coil across participants. Overall, the median g-factors for the 16-channel AIR coil were less than those of the 8-channel coil but greater than those of the 32-channel coil.
"The advantages of the AIR coil technology for reduction of claustrophobia, improved airway access and monitoring of patients under anesthesia, and overall better user comfort may be investigated in future studies," the authors of this AJR article added.
For more information: www.arrs.org
March 20, 2023 
![A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients](/sites/default/files/styles/feed_medium/public/Screen%20Shot%202023-03-16%20at%201.46.39%20PM.png?itok=a2-uUeQz)
